# Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL

> **NCT04908228** · PHASE2 · RECRUITING · sponsor: **Paolo Ghia** · enrollment: 53 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Ibrutinib and obinutuzumab

## Key facts

- **NCT ID:** NCT04908228
- **Lead sponsor:** Paolo Ghia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-13
- **Primary completion:** 2026-09-15
- **Final completion:** 2027-09-15
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2023-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04908228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04908228, "Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04908228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*